Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 7Colorectal Neoplasms 4Stomach Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma Of Esophagus 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Meningeal Neoplasms 1HER2-positive Breast Cancer 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Cholangiocarcinoma 1Brain Neoplasms 1Biliary Tract Neoplasms 1Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

Paclitaxel 6Radiotherapy 2Pemetrexed 2Carboplatin 2Brachytherapy 2tucatinib 1seribantumab 1osimertinib 1gedatolisib 1fosaprepitant 1fluciclovine F-18 1cobimetinib 1atezolizumab 1alovudine 1Trastuzumab 1Therapeutics 1TP protocol 1Saline Solution 1Radiation 1Protons 1Palliative Care 1Nivolumab 1Letrozole 1Immunoglobulin G 1Imatinib Mesylate 1Ifosfamide 1Gemcitabine 1Fulvestrant 1FANG vaccine 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Uterine Neoplasms × tucatinib × Clear all
NCT04579380 2025-12-19

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Seagen Inc.

Phase 2 Active not recruiting
217 enrolled 19 charts
BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡